DNTH

Over the past six months, Dianthus Therapeutics' shares have seen a substantial increase, rising by 110.7% since the start of 2026. In March 2026, the company announced an early "GO" decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19.4% surge in the stock price. In March 2026, Dianthus Therapeutics closed an upsized underwritten public offering, raising approximately $719 million in gross proceeds. On May 5, 2026, the company reported its financial results for the first quarter ending March 31, 2026, highlighting recent business achievements. Claseprubart was granted Orphan Drug Designation by the FDA for Myasthenia Gravis. In the past three months, Dianthus Therapeutics insiders sold $26,564,008.00 in company stock, with no insider buying reported. The company granted inducement equity awards to newly hired non-executive employees in May and April 2026. Successful Phase 2 "MaGic" trial data in generalized Myasthenia Gravis (gMG) in late 2025 contributed to a significant appreciation in the stock price over the preceding 12 months.